Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.1K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.1K
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

1.7K
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

686
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
686

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria - Insights from the UCARE/ADCARE PROMUSE study.

The World Allergy Organization journal·2026
Same author

Skin Allergy Research Society and Society for Eczema Studies Joint Task Force Guidelines of Care for Management of Atopic Dermatitis for Adults, Children, and Special Populations in India: An Evidence-Based Review and an Expert Consensus.

Indian journal of dermatology·2026
Same author

Expert Consensus on the Rational Approach to Isotretinoin Usage for Effective Management of Acne: ERAISE ACNE Recommendations.

Dermatology and therapy·2026
Same author

Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study.

American journal of clinical dermatology·2026
Same author

Translation and Validation of Urticaria Control Test (UCT) and Chronic Urticaria Quality of Life (CU-Q2oL) Questionnaires in Hindi.

Indian journal of dermatology·2026
Same author

Key Predictors of Adherence to a Mobile Health App for Managing Chronic Spontaneous Urticaria.

Clinical and translational allergy·2025
Same journal

Severe Irritant Contact Dermatitis to <i>Cyperus Scariosus</i>: A Side Effect of Ayurvedic <i>Plava</i>.

Indian journal of dermatology·2026
Same journal

Extensive Grouped Papules on the Vulva in a Patient with Cervical Cancer.

Indian journal of dermatology·2026
Same journal

Facial Melanosis: A Comprehensive Review of Uncommon and Common Presentations with Personal Experience.

Indian journal of dermatology·2026
Same journal

Exploring AI as a Diagnostic Tool in Medical Imaging for Dermatopathological Diseases.

Indian journal of dermatology·2026
Same journal

Carotid Intima-Media Thickness and Retrobulbar Blood Flow in Patients with Psoriasis.

Indian journal of dermatology·2026
Same journal

Pyoderma Gangrenosum-Like Ulcer Secondary to Antiphospholipid Syndrome.

Indian journal of dermatology·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.2K

Omalizumab-A Review.

Kiran Godse1, Aayushi Mehta1, Sharmila Patil1

  • 1Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Nerul, Navi Mumbai, India.

Indian Journal of Dermatology
|August 20, 2015
PubMed
Summary
This summary is machine-generated.

Omalizumab, a monoclonal antibody targeting immunoglobulin E (IgE), is now FDA-approved for chronic urticaria. This treatment offers a new option for patients with this chronic skin condition.

Keywords:
AnaphylaxisFDA approvalatopic dermatitischronic urticariamonoclonal antibody

More Related Videos

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

12.5K
Zika Virus Specific Diagnostic Epitope Discovery
11:37

Zika Virus Specific Diagnostic Epitope Discovery

Published on: December 12, 2017

8.4K

Related Experiment Videos

Last Updated: Apr 5, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.2K
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

12.5K
Zika Virus Specific Diagnostic Epitope Discovery
11:37

Zika Virus Specific Diagnostic Epitope Discovery

Published on: December 12, 2017

8.4K

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Chronic urticaria is a debilitating skin condition characterized by recurrent hives and angioedema.
  • Current treatments for chronic urticaria have limitations in efficacy and safety for some patients.
  • Human immunoglobulin E (IgE) plays a key role in the pathophysiology of chronic urticaria.

Purpose of the Study:

  • To evaluate the efficacy and safety of omalizumab in patients with chronic urticaria.
  • To assess the impact of omalizumab on disease activity and quality of life in chronic urticaria patients.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials.
  • Inclusion of studies evaluating omalizumab versus placebo or other active treatments.
  • Assessment of primary endpoints such as urticaria activity scores and secondary endpoints including quality of life measures.

Main Results:

  • Omalizumab demonstrated significant improvements in urticaria activity scores compared to placebo.
  • Patients treated with omalizumab reported enhanced quality of life.
  • The safety profile of omalizumab was consistent with previous findings, with generally well-tolerated adverse events.

Conclusions:

  • Omalizumab is an effective and safe therapeutic option for patients with chronic urticaria.
  • Targeting IgE with omalizumab represents a significant advancement in the management of chronic urticaria.
  • Further research may explore long-term efficacy and optimal treatment duration.